Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 3Gastrointestinal 2Breast 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × GSK 1363089 × Breast × Clear all
NCT01138384 2023-08-04

Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 1/2 Completed
19 enrolled
Breast

Breast Neoplasms

NCT01147484 2023-08-04

IND197

Canadian Cancer Trials Group

Phase 2 Completed
47 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡